| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-031 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份74.3753万股（占剔除已回购股份后总股本比例0.37%）的股东吴希 罕先生计划在2025年5月9日至2025年8月8日以集中竞价方式或大宗交易方式减持本公 司股份74.3753万股（占剔除已回购股份后总股本比例0.37%）。 一、股东情况 （一）股东名称：吴希罕 （二）股东持股数量：截至本公告披露日，吴希罕先生持有公司股份数74.3753万 股，占剔除已回购股份后总股本比例0.37%。 南京药石科技股份有限公司 关于公司股东减持股份的预披露公告 公司股东吴希罕保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （六）减持价格区间：根据减持时的二级市场价格及交易方式确定。 （七）股东承诺履行情况：截至本公告日，吴希罕先生严格遵守了《首次公开发 行股票并在创业板上市招股说明书》和《首次公开发行股票并在 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-029 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届董事会第五次会议 于2025年4月30日以书面审议会议文件、传签表决的方式召开。会议通知已于2025 年4月27日通过电子邮件方式送达各位董事。会议由董事长杨民民先生召集主持， 应出席董事人数7人，实际出席董事人数7人。本次会议的召集、召开符合《中华 人民共和国公司法》和《南京药石科技股份有限公司公司章程》等有关规定。 一、 董事会会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 1、审议通过了《关于审议公司 2024 年环境、社会及公司治理报告的议案》 具 体 内 容 详 见 公 司 于 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.c ...

公司近日接到股东杨民民先生函告，获悉其所持有本公司的部分股份接触质押， 具体事项如下： | 股东 | 是否为第一大股 | 本次解除质押股 | 占其所持股 | 占公司总股 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及一致行动人 | 份数量（股） | 份比例（%） | 本比例（%） | | | | | 华泰证券（上 | 2024年4月 | 2025年4月 | | | | | | | 杨民民 | 是 | 2,000,000 | 4.83 | 1.00 | 海）资产管理 | 29日 | 29日 | | 有限公司 | | | | | | | | 二、股东股份累计被质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-030 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.689 billion yuan in 2024, a year-on-year decline of 2.12%, while the net profit attributable to the parent company was 220 million yuan, an increase of 11.24% year-on-year. In Q1 2025, the company reported a revenue of 455 million yuan, a year-on-year growth of 20.55%, but the net profit attributable to the parent company decreased by 27.67% year-on-year [4][5] - The company has a steady growth in its order backlog, leading to an upward revision of profit forecasts for 2025-2027, with expected net profits of 255 million, 298 million, and 364 million yuan respectively [4][5] Financial Performance - In 2024, the company's revenue from drug development and commercialization services was 1.354 billion yuan, a decrease of 1.83% year-on-year. The revenue from CDMO services was 863 million yuan, an increase of 3.38% year-on-year. Domestic revenue was 449 million yuan, down 17.47%, while international revenue was 1.24 billion yuan, up 4.94% [5][6] - The company signed new CDMO orders worth 12.43% more than the previous year, with the number of active clients increasing by 12.32% to 775 [6] Market Expansion - The company has made significant progress in expanding its overseas market, with European revenue growing by 40.12% year-on-year to 193 million yuan in 2024. North American revenue remained stable at 979 million yuan [5][6] - The company has strengthened its collaboration with multinational pharmaceutical companies, achieving a revenue of 464 million yuan from MNC clients, a year-on-year increase of 16.37% [6] Earnings Forecast - The earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 1.28, 1.49, and 1.82 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 24.7, 21.1, and 17.3 [4][8]

2025 年 04 月 29 日 药石科技(300725.SZ) 订单逐步改善，期待公司经营边际优化 事件： 公司发布了 2024 年年度报告和 2025 年第一季度报告，2024 年公司 分别实现营收和归母净利润 16.89 亿元和 2.20 亿元，分别同比下降 2.12%和同比增长 11.24%；2025Q1 公司分别实现营收和归母净利润 4.55 亿元和 0.36 亿元，分别同比增长 20.55%和同比下降 27.67%。 受产品价格竞争和短期盈利能力承压等影响，2025Q1 业绩暂时 性下滑： 2024 年公司分别实现营收和归母净利润 16.89 亿元和 2.20 亿元，分 别同比下降 2.12%和同比增长 11.24%。其中，2024 年药物研究阶段 的产品和服务、药物开发及商业化阶段的产品和服务分别贡献营收 3.31 亿元（-4.06%）、13.54 亿元（-1.83%）。 2025Q1 公司分别实现营收和归母净利润 4.55 亿元和 0.36 亿元，分 别同比增长 20.55%和同比下降 27.67%。其中，2025Q1 药物研究阶段 的产品和服务、药物开发及商业化阶段的产品和服务分别贡献营收 ...

Financial Performance - Total revenue for 2024 was 1.689 billion CNY, a decrease of 2.12% year-on-year [6] - Operating cash flow increased by 22.68% to 303 million CNY [6] - Net profit attributable to shareholders rose by 11.24% to 220 million CNY [6] - Earnings per share reached 1.10 CNY, an increase of 12.43% [6] - Gross margin was 38.06%, down by 4.46 percentage points year-on-year [6] Revenue Breakdown - Revenue from drug development and commercialization was 1.354 billion CNY, down 1.83% year-on-year [8] - Revenue from drug research stage products and services was 331 million CNY, a decrease of 4.06% [8] - Revenue from molecular building blocks for drug discovery was 281 million CNY; for drug development and production, it was 491 million CNY [9] Customer Segmentation - Revenue sources by type: 28% from large multinational pharmaceutical companies and 72% from small and medium-sized biopharmaceutical companies [12] - Revenue sources by region: North America contributed 58% (979 million CNY), Europe 11% (193 million CNY), China 27% (449 million CNY), and Japan/Korea and others 4% (68 million CNY) [12] Project Pipeline - Over 2,400 projects in various stages, with 78 projects in clinical phases [15] - Focus on early clinical projects to strengthen later-stage project growth [14] Innovation and Technology - Cumulative design of over 200,000 novel molecular building blocks, with over 45,000 compounds synthesized [23] - Development of unique solutions to accelerate new drug research, including an AI-driven drug discovery platform [27] - Continuous flow chemistry and low-carbon technology innovations are key to sustainable development [50] ESG Commitment - Achieved AA rating in Wind ESG assessment and joined the UN Global Compact [72] - Received multiple awards for sustainability and green chemistry excellence [52] Future Strategy - Focus on enhancing customer value creation and strengthening technology transformation capabilities [75] - Aim to improve delivery quality and build trust with customers [76]

Group 1: Company Performance and Growth - In 2024, the company experienced a 30% year-on-year growth in API and GMP intermediate projects at Zhejiang Huishi, with 4 new NDA projects added [3] - The CDMO new signed order amount in 2024 increased by 12.43%, with order quantity rising by 31.12% [9] - The company’s revenue from multinational pharmaceutical companies grew by 16.37%, contributing 27.50% to total revenue [9] Group 2: Market Expansion and Client Acquisition - The company has established a 5-person BD team in Europe and appointed a BD head for Japan and South Korea to enhance market share [2] - By the end of 2024, the company entered multiple top 10 multinational pharmaceutical companies' direct procurement platforms, significantly boosting sales [8] - The company aims to increase the application of new technologies in production from 20% in 2024 to 30% or higher [4] Group 3: Financial Metrics and Cost Management - The gross margin for the CDMO business in 2024 was 31.57%, expected to remain stable in Q1 2025 [10] - The company plans to maintain stable absolute amounts for expenses in 2025 while reducing expense ratios alongside revenue growth [14] - The human resource cost accounted for 35.30% of revenue, with a 14.69% increase in fixed asset depreciation impacting overall costs [17] Group 4: Product Development and Innovation - The company is focusing on developing new molecular building blocks for small molecule GLP-1 projects, leveraging early market positioning [15] - The R&D team is enhancing efficiency by utilizing AI technology for new product design starting in 2024 [8] - The company plans to expand its R&D capabilities at the Nanjing center to support future business growth [12] Group 5: Response to Market Conditions - The company is closely monitoring changes in U.S. tariff policies, with 70% of revenue from U.S. and European clients, and 20% directly from the U.S. market [6][7] - The company is implementing strategies to mitigate the impact of tariff fluctuations, including enhancing European market presence and optimizing contract terms [7] - The company anticipates structural pressures on demand from small biotech companies due to global investment cycles [9]

Summary of the Conference Call for YaoShi Technology Company Overview - **Company**: YaoShi Technology - **Year**: 2024 - **Revenue**: 1.684 billion CNY, a year-on-year increase of 11% [2][3] - **Earnings per Share**: 1.1 CNY, a year-on-year increase of 11% [2][3] - **Operating Cash Flow**: 303 million CNY, a year-on-year increase of 22.68% [2][3] - **New CDS Orders**: Increased by 12.43% [2][3] Revenue Structure - **Drug Development Revenue**: Decreased by 4% to 330 million CNY [2][3] - **CDMO Business**: Remained stable at 1.354 billion CNY [2][3] - **Revenue Contribution**: Large multinational pharmaceutical companies contributed 464 million CNY (28%), while small and medium-sized biotech companies contributed 1.224 billion CNY (72%) [3][4] Market Expansion and Client Growth - **Global Clients**: Over 1,000 clients, with active clients increasing by over 12% [2][5] - **New Clients**: 258 new clients, a year-on-year increase of over 65% [2][5] - **Geographical Revenue**: North America accounted for 57%, Europe 11%, and China 26% [13][14] Operational Highlights - **Clinical Projects**: Completed over 2,400 projects from preclinical to phase II and 78 phase III and commercialization projects [2][4] - **GMP Delivery Capability**: Strengthened with a 30% increase in API and GMP intermediate projects at the Zhejiang Huishi production base [2][5] - **New NDA Projects**: Four new raw material drug NDA projects, three of which were approved [2][5] Strategic Initiatives - **Market Focus**: Continued expansion in Europe, Japan, and South Korea, with a focus on multinational pharmaceutical collaborations [2][7] - **New Technology Application**: Aiming to increase the proportion of new technology applications in production projects from 20% to over 30% [2][8] - **Non-Pharmaceutical Ventures**: Expanded into non-drug areas, particularly in photoresist, with new business collaborations [2][9] Financial Performance and Projections - **Gross Margin**: 38.06%, a year-on-year decrease of 4.46% [3] - **CDMO Orders**: Increased by 12% in order value and over 30% in order quantity [3][13] - **Future Cost Management**: Expected continued reduction in expense ratios in 2025 [15] Challenges and Responses - **Geopolitical Factors**: 70% of business concentrated in Europe and the U.S., with manageable impacts from tariffs [11] - **R&D and Production Capacity**: New production facilities and continuous improvement in capacity utilization [19][20] Future Directions - **Strategic Planning**: Focus on quality, innovation, and digital transformation [27] - **New Molecular Types**: Significant achievements in peptide and oligonucleotide sectors, with ongoing demand from large foreign companies [21][22] - **Warehouse Development**: Establishing warehouses in Europe and expanding U.S. market presence [23] Conclusion YaoShi Technology is positioned for growth with a strong focus on expanding its market presence, enhancing operational capabilities, and leveraging new technologies to drive future success. The company is actively addressing challenges while maintaining a positive outlook for continued revenue and client growth.

据证券之星公开数据整理，近期药石科技(300725)发布2025年一季报。截至本报告期末，公司营业总收 入4.55亿元，同比上升20.55%，归母净利润3579.08万元，同比下降27.67%。按单季度数据看，第一季 度营业总收入4.55亿元，同比上升20.55%，第一季度归母净利润3579.08万元，同比下降27.67%。本报 告期药石科技公司应收账款体量较大，当期应收账款占最新年报归母净利润比达165.21%。 本次财报公布的各项数据指标表现一般。其中，毛利率30.34%，同比减28.94%，净利率7.87%，同比减 40.0%，销售费用、管理费用、财务费用总计6827.0万元，三费占营收比15.0%，同比减18.25%，每股净 资产14.51元，同比增5.4%，每股经营性现金流1.26元，同比增355.92%，每股收益0.18元，同比减28.0% | 项目 | 2024年一季报 | 2025年一季报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.77亿 | 4.55 Z | 20.55% | | 归母净利润(元) | 4948.54万 | 3579. ...